Type 2 & other diabetes

PIONEER REAL Saudi Arabia: A multicentre, prospective, real‐world study of once‐daily oral semaglutide use in adults with type 2 diabetes in Saudi Arabia

Diabetes Obes MetabPublished Prospective real-world study

Authors' conclusion

This real-world population of adults with T2D in Saudi Arabia experienced clinically significant reductions in HbA1c and BW, increased treatment satisfaction and a favourable safety profile, consistent with previously published PIONEER REAL studies.

Study context

Population
Adults with T2D, treatment-naive to injectable glucose-lowering medication, Saudi Arabia; baseline mean age 51.7 years, mean HbA1c 8.0%, mean body weight (BW) 90.5 kg139 completed
Participants
192 adults
Outcome
Change in HbA1c from baseline to end of study (EoS)
Follow-up
34–44 weeks
Methodological detailsmulticentre, open-label, single-arm
  • Multicentre
  • Open-label
  • Single-arm

Main finding

As reported in the abstract

Change in HbA1c from baseline to EoS · EoS (34–44 weeks)

Estimated mean change in HbA1c (SE 0.09; p < 0.0001)

−1.0%-points

Observational data: associations, not effects.

Further findings

Change in BW from baseline to end of study (EoS)

Estimated mean change in BW (SE 0.51; p < 0.0001)
−4.4 kg

Change in waist circumference (WC) from baseline to EoS

Estimated mean change in WC (SE 0.62; p < 0.0001)
−4.3 cm

HbA1c <7% · EoS

Participants with HbA1c <7%
61.9%

HbA1c reduction ≥1% with BW reduction ≥3% or ≥5% · EoS

HbA1c ↓≥1% and BW ↓≥3%
21.9%
HbA1c ↓≥1% and BW ↓≥5%
17.1%

Treatment satisfaction · EoS

Mean change in Diabetes Treatment Satisfaction Questionnaire-status (DTSQs) (p < 0.0001)
+8.7
Mean change in DTSQc (p < 0.0001)
14.9

Remaining on oral semaglutide · EoS

Remained on oral semaglutide
49.5%
Of those, receiving 14.0 mg dose
47.4%

Original publication

PIONEER REAL Saudi Arabia: A multicentre, prospective, real‐world study of once‐daily oral semaglutide use in adults with type 2 diabetes in Saudi Arabia. Diabetes Obes Metab. Published 27 November 2025. doi:10.1111/dom.70317

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.